Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001

SAN FRANCISCO, March 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. AKRO today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, in a pre-market press release and webcast to be held on Tuesday, March 31, 2020.

Conference Call / Webcast Details
The company will host a conference call and webcast with slide presentation at 8:30 a.m. ET (5:30 a.m. PT) tomorrow morning, March 31. The conference call will be made available on the company's website at www.akerotx.com under the Investors tab in the Events, Presentations & Webcasts section. To access the call via dial-in, please dial 1-866-652-5200 (U.S. toll free) or 1-412-317-6060 (international) five minutes prior to the start time. Following the live audio webcast, a replay will be available on the company's website for 90 days.

About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in San Francisco, CA. For more information, please visit www.akerotx.com.

SOURCE Akero Therapeutics, Inc.